Replimune Group, Inc.·4

Dec 18, 9:00 PM ET

Patel Sushil 4

4 · Replimune Group, Inc. · Filed Dec 18, 2024

Insider Transaction Report

Form 4
Period: 2024-12-16
Patel Sushil
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    2024-12-16$12.42/sh10,000$124,200202,014 total
Footnotes (3)
  • [F1]The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on April 3, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
  • [F2]The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.62. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]Following the sales reported on this Form 4, the reporting person continues to beneficially own 202,014 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 513,750 shares of the Issuer's common stock, 189,478 of which are exercisable as of the date hereof.

Documents

1 file
  • 4
    tm2431484-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT